News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ADMA Biologics, Inc. Secures Up to $6 Million Term Loan Commitment to Advance Phase III Study


1/7/2013 10:00:27 AM

HACKENSACK, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc.(ADMA), a late-stage biotechnology company focused on developing specialty immune globulin therapeutics and the commercialization of human plasma, announced it has entered into a $6 million term loan commitment with Hercules Technology Growth Capital, Inc., (Hercules: NYSE: HTGC).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES